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ABSTRACT
Background
Large quantities of smallpox vaccine have been stockpiled to protect entire nations against a
possible reintroduction of smallpox. Planning for an appropriate use of these stockpiled
vaccines in response to a smallpox outbreak requires a rational assessment of the risks of
vaccination-related adverse events, compared to the risk of contracting an infection. Although
considerable effort has been made to understand the dynamics of smallpox transmission in
modern societies, little attention has been paid to estimating the frequency of adverse events
due to smallpox vaccination. Studies exploring the consequences of smallpox vaccination
strategies have commonly used a frequency of approximately one death per million
vaccinations, which is based on a study of vaccination with the New York City Board of
Health (NYCBH) strain of vaccinia virus. However, a multitude of historical studies of smallpox
vaccination with other vaccinia strains suggest that there are strain-related differences in the
frequency of adverse events after vaccination. Because many countries have stockpiled vaccine
based on the Lister strain of vaccinia virus, a quantitative evaluation of the adverse effects of
such vaccines is essential for emergency response planning. We conducted a systematic review
and statistical analysis of historical data concerning vaccination against smallpox with different
strains of vaccinia virus.
Methods and Findings
We analyzed historical vaccination data extracted from the literature. We extracted data on
the frequency of postvaccinal encephalitis and death with respect to vaccinia strain and age of
vaccinees. Using a hierarchical Bayesian approach for meta-analysis, we estimated the expected
frequencies of postvaccinal encephalitis and death with respect to age at vaccination for
smallpox vaccines based on the NYCBH and Lister vaccinia strains. We found large
heterogeneity between findings from different studies and a time-period effect that showed
decreasing incidences of adverse events over several decades. To estimate death rates, we then
restricted our analysis to more-recent studies. We estimated that vaccination with the NYCBH
strain leads to an average of 1.4 deaths per million vaccinations (95% credible interval, 0–6) and
that vaccination with Lister vaccine leads to an average of 8.4 deaths per million vaccinations
(95% credible interval, 0–31). We combined age-dependent estimates of the frequency of death
after vaccination and revaccination with demographic data to obtain estimates of the expected
number of deaths in present societies due to vaccination with the NYCBH and Lister vaccinia
strains.
Conclusions
Previous analyses of smallpox vaccination policies, which rely on the commonly assumed
value of one death per million vaccinations, may give serious underestimates of the number of
deaths resulting from vaccination. Moreover, because there are large, strain-dependent
differences in the frequency of adverse events due to smallpox vaccination, it is difficult to
extrapolate from predictions for the NYCBH-derived vaccines (stockpiled in countries such as
the US) to predictions for the Lister-derived vaccines (stockpiled in countries such as Germany).
In planning for an effective response to a possible smallpox outbreak, public-health decision
makers should reconsider their strategies of when to opt for ring vaccination and when to opt
for mass vaccination.
The Editors’ Summary of this article follows the references.
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With concerns rising that the smallpox virus could be used
in a bioterrorist attack, many countries have been planning
vaccination programs in case an outbreak of smallpox occurs.
Most of the vaccines stockpiled are ﬁrst-generation vaccines,
as were used during the World Health Organization (WHO)
smallpox-eradication campaign. Considering the large num-
ber of unvaccinated people in present societies, the question
arises about how many people would be expected to have
serious adverse events, such as postvaccinal encephalitis (PVE
[1,2]) or death, after smallpox vaccination. Because PVE had a
case-fatality rate of approximately 25%–30%, with 16%–30%
of survivors having permanent neurological damage [1,2], the
WHO promoted the switch to the Lister strain of vaccinia
virus for vaccine production in the 1950s. It has been shown
that vaccinia strains differ in their pathogenicity in animals
[3] and that vaccinia strains that are more pathogenic in
animals may cause a higher rate of postvaccinal complica-
tions in humans after vaccination [4].
Recent experience during a smallpox vaccination campaign
in the US demonstrated clearly the importance of precise
knowledge of the frequency of adverse events after vaccina-
tion. In a two-pronged program, more than 40,000 civilians
and more than 700,000 military personnel were vaccinated
between December 2002 and January 2005 [5]. The vaccina-
tion program for the military and civilian personnel of the US
Department of Defense is ongoing, and, as of April 2006, the
number of people screened exceeds 1,090,000, with more than
1 million having been vaccinated since December 2002 (J.
Grabenstein, personal communication). The frequency of
adverse events that was anticipated on the basis of historical
data was lower than expected. However, a higher-than-
anticipated number of vaccination-related myopericarditis
cases led to much publicity of and controversy about the
program [6]. Although the occurrence of vaccination-related
adverse events cannot be precluded, this experience shows the
importance of using the knowledge we have from previous
vaccination campaigns during planning for future campaigns
[7]. Precise estimates of the frequencies of adverse events and
their credible intervals (CIs) are essential for deﬁning thresh-
olds for stopping or switching vaccination programs.
Mathematical modeling has played a central role in the
development of plans to respond to a smallpox outbreak [8–
13], because it provides a tool to rigorously test the effects of
different vaccination strategies and analyze the inﬂuence of
various interventions in a situation in which there is no
naturally occurring infection. In many of these modeling
studies, estimates of the number of deaths associated with a
smallpox vaccination campaign were computed on the basis
of the commonly cited mortality rate of one death per million
vaccinations that was derived from the surveys by Lane et al.
[14] and Neff et al. [15]. Recently, US studies about the
adverse effects of smallpox vaccination with the New York
City Board of Health (NYCBH) vaccinia strain that were
published by Lane et al. [14,16], Neff et al. [15,17], and others
were reviewed by Arago ´n et al. [18].
However, model ﬁndings based on the adverse effects of
the NYCBH strain might not hold for the Lister strain, which
is stockpiled in Great Britain, Germany, the Netherlands, and
other European countries. Even less is known about the
frequency of adverse events after vaccination with other
vaccinia strains that might still be in use in Asian countries.
An analysis of the existing data on the frequency of adverse
events after vaccination with different vaccinia strains can
provide some evidence of the variability between strains. At
present, efforts are under way to develop third-generation
vaccines based on attenuated strains of vaccinia virus, such as
modiﬁed vaccinia Ankara (MVA) and LC16m8 [19,20]. The
latter strain, which is based on the Lister strain and is
currently licensed in Japan for use in smallpox vaccine, was
administered to more than 100,000 infants during 1973–1975
without serious adverse events and is viewed as a serious
candidate for a third-generation vaccine. Although there are
many reports scattered in the literature on the adverse effects
of smallpox vaccination with vaccinia strains other than
NYCBH, those studies are often difﬁcult to access and
published in languages other than English.
In our study, we collected data from reports involving a
variety of countries, periods, and age groups on vaccinations
with and adverse events due to different vaccinia strains. On
the basis of these data, we conducted a meta-analysis using
Bayesian methods and obtained estimates for the frequency
of adverse events after smallpox vaccination with respect to
age and vaccinia strain. Here, we report age-related and
strain-related ﬁndings on the occurrence of PVE and death
after primary vaccination and revaccination with vaccinia
virus. We combined age-dependent estimates with demo-
graphic data about the age structure of a population targeted
for vaccination to derive estimates and CIs of the rate of
adverse events, including death, to be expected during a
targeted smallpox vaccination program.
Data Sources
We conducted a systematic search of the literature using
Medline and the social medicine and public health database
that is located at the German Institute of Medical Documen-
tation and Information. Furthermore, we iteratively scanned
references cited in each of the identiﬁed articles for any
additional studies. For data speciﬁcally about Germany, we
searched the ‘‘Bundesgesundheitsblatt’’ (a German medical
journal) from 1959 to 1985. We extracted data about numbers
of primary vaccination and revaccination, age groups, strains,
and frequencies of adverse events. In addition to the studies
reviewed by Arago ´n et al. [18], we were able to extract a
considerable amount of information about vaccinations in
Germany, Austria, Sweden, the UK, France, the former Soviet
Union, and the Netherlands (see Table 1). There was huge
variation in the detail of reporting between the various
studies. For the analysis, we categorized the studies according
to whether the following types of information were reported:
numbers of primary vaccination and revaccination, age at the
time of primary vaccination and revaccination, types and
frequencies of adverse events, age at which adverse events
occurred, vaccinia strain used, and the time of vaccination.
Articles that did not clearly distinguish between primary
vaccination and revaccination were excluded from our
analysis. For the analysis of the effect of age on the frequency
of adverse events, we included only studies that reported both
age at vaccination and age at which adverse events occurred
(although broad age categories were often used). Some studies
were excluded because the reporting time and study
population overlapped those of other studies. Of the US
studies, we chose to use the national surveillance data
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from the state surveys. The reason for this decision was that
the national data are believed to be more reliable, because
they were better validated (D. Henderson, personal commu-
nication). The state reports included large numbers of trivial
rashes and other minor adverse events and were not designed
to document valid rates of serious events, such as PVE or
death [21]. So, although the national reports may suffer from
some under-reporting, the cases that they report are better
validated.
The vaccinia strains used in different countries were
reported only occasionally in the articles. We included
studies for which information about the strain could be
obtained from the article itself or from other reliable sources.
In all studies in the US, the NYCBH strain was used. In
Europe, different strains were used in different countries,
regions, and periods. In Germany and Austria in the 1950s
and 1960s, the Bern strain was used most often [22]. In the
former Soviet Union, the EM-63 strain, which was derived
from the NYCBH strain, was used until 1971 [22]. In the UK,
the Lister-Elstree strain was developed and used [23]. In the
Netherlands, the Copenhagen strain was used until 1962,
after which the Lister-Elstree strain was used [24]. In 1968, in
an effort to standardize vaccines worldwide and ensure
vaccine quality, the WHO recommended that either the
NYCBH strain or the Lister strain be used in the worldwide
eradication campaign [22]. In both France and Sweden, the
Lister strain was used during the times that the data we used
here were originally recorded (personal communication with
public health ofﬁcials in the respective national public health
institutes). In the former East Germany, the Berlin strain was
used, according to information from the Robert Koch
Institute (Berlin, Germany). Unknown strains or strains for
which too few data were available to make a separate
evaluation possible were grouped into the category ‘‘other.’’
Methods
Estimating the frequency of rare adverse events from a
number of studies presents a methodological problem,
because many studies of limited size will report counts of
zero. Standard meta-analytic methods, such as those described
by Sutton et al. [25], are not well suited to deal with zero
counts. We used Bayesian methods to deal with the extremely
low but positive probabilities that lead to frequent occurrence
of zero counts in the data. Moreover, Bayesian methods
provide a natural framework for dealing with a hierarchical
model structure and uncertainties. The technical details of
our approach can be found in Protocol S1 and Table S1.
The analysis was conducted in several steps. First, the effects
of the study methodology and the times of data collection on
the incidence of PVE were analyzed (Figure 1). In this article,
we use the term ‘‘incidence’’ to express number of adverse
events per number of vaccinations, without reference to a
time unit. We used the midpoint of the reported time of
vaccination as a point estimate for the time corresponding to
the study data. We estimated the incidences for the different
studies with the age-independent hierarchical model (i.e., the
model with us(a) [ 1; compare Protocol S1). This analysis
revealed that earlier studies reported a much higher incidence
of adverse events than studies conducted in the 1960s and
later (Figure 1A). Therefore, to exclude time trends we used
only the more recent studies for the further analysis and
estimation. Using data from 1958 onwards, we conducted an
analysis with the age-independent model to investigate the
effects of different vaccinia strains on the frequency of PVE
and death (Figure 2). Using the model with age dependence,
we then extended the analysis to study the effects of age and
vaccinia strain on the frequency of PVE and mortality (Figure
3). Finally, for the NYCBH, Lister, and Bern strains, age-
dependent data about the occurrence of PVE and death after
revaccination were analyzed (again, only data from 1958
onwards were used) (Figure 4). Combining primary vaccina-
tion and revaccination results with demographic information
and information about previous vaccinations in the present
population, one can estimate the number of expected cases of
PVE and death after mass vaccination with the above vaccinia
strains. We provide such estimates for populations in the
Netherlands and Germany.
The estimates we report are means of the posterior
distribution. Variability of the estimates is described in terms
of 95% CIs, which contain 95% of the mass of the density of
the posterior distribution. Data in the category ‘‘other’’ were
included in the statistical analysis for the sake of complete-
ness, but we do not discuss the ﬁndings for these data further
because they cannot be interpreted in terms of speciﬁc
vaccinia strains.
Results
Relationship between Study Period and the Reported
Incidence of PVE after Primary Vaccination
The estimated incidences of PVE after primary vaccination
in studies conducted in different periods showed a clear
trend toward lower incidences in more-recent periods
(Figure 1A). This was consistent for all strains for which
information is available from several decades of reporting.
The trend seemed to stabilize in approximately 1960, which
led us to take the year 1957 as a cutoff point for distinguish-
ing between earlier and later periods of study. This trend
toward lower incidences can be explained by improved
vaccine production methods, quality control (as advocated
by the WHO), and health-care and vaccination procedures
[22]. It could also be a consequence of better case ascertain-
ment that led to a reduced number of adverse events that
were misdiagnosed as PVE. It is to be expected that effects
associated with present use of a smallpox vaccine will
resemble the effects of a similar vaccine administered after
1957. Therefore, in the further analysis, we concentrated on
analyzing those studies whose midpoint of observation was no
earlier than 1958, the year that marks the introduction of the
ﬁrst WHO standards for smallpox vaccine [22], which
followed a study by Cockburn et al. [26].
Frequency of PVE after Primary Vaccination
For primary vaccinations, we found large differences in the
frequency of PVE between vaccine strains (Figure 2A and
Table S2). We found that the Bern strain caused by far the
highest rate of PVE, with 44.9 expected cases of PVE per
million vaccinations, followed by the Copenhagen strain, with
33.3 expected cases per million vaccinations. The Lister strain
caused an intermediate rate of PVE, with an expected
number of 26.2 cases per million vaccinations, whereas the
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Adverse Events and Vaccinia StrainsFigure 1. Variability among Studies in the Frequency of PVE
(A) The estimated frequency of PVE after primary vaccination in different studies. The symbols mark the midpoint of the interval during which
vaccinations reported in the study were performed. The dashed line indicates the separation line between periods that was used for the Bayesian
analysis. All studies to the right of the separation line were used for further analysis. The error bars indicate the 95% CIs of the estimates. The data
shown in this figure come from the studies marked in the column ‘‘time period effect’’ of Table 1.
(B) The logarithm of the incidence of PVE (defined as the number of PVE cases per 1 million vaccinations) by age for different strains, as reported in
various studies (blue, NYCBH; red, Bern; green, Lister). The age is plotted on a log10 scale for visual clarity.
DOI: 10.1371/journal.pmed.0030272.g001
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Adverse Events and Vaccinia StrainsNYCBH strain was the most benign, with only 2.9 cases per
million vaccinations.
With regard to age-related effects, we found different age-
dependent patterns of PVE for the various strains (Figure 1B).
For the NYCBH strain, the frequency of PVE was highest
among persons  1 y of age, it decreased to a minimum for
persons aged .1–3 y, and it increased again for persons aged
.3 y. For the Bern, Lister, and Copenhagen strains, we saw a
monotonous increase in the frequency of PVE with increasing
age. For vaccination with the NYCBH strain, we determined
that there would be approximately four cases per million
vaccinations in children younger than 1 y (95% CI, 0–14); for
the Lister strain, we expect 15 cases per million vaccinations
(95% CI, 1–48); for the Bern strain, we expect 46 cases per
million vaccinations (95% CI, 10–107); and for the Copenha-
gen strain, we expect 36 cases per million vaccinations (95%
CI, 3–118) (Figure 3A).
Vaccination-Related Mortality after Primary Vaccination
A similar pattern emerged for vaccination-related mortal-
ity. We analyzed the number of all deaths attributed to
vaccination and the number of deaths attributed speciﬁcally
to PVE. With respect to overall mortality, the Bern strain was
again the strain with the highest vaccination-related mortal-
ity, with 55.0 deaths per million primary vaccinations (95%
CI, 2–207) expected. For the Copenhagen strain, we expect
31.2 deaths per million vaccinations (95% CI, 2–105); for the
Lister strain, we expect 8.4 deaths per million vaccinations
(95% CI, 0–31); and for the NYCBH strain, we expect only 1.4
deaths per million vaccinations (95% CI, 0–6). Analysis of the
number of deaths that are related to PVE only revealed that,
for the Bern strain, there would be 11.0 deaths per million
vaccinations (95% CI, 1–30); for the Copenhagen strain, there
would be 16.5 deaths per million vaccinations (95% CI, 0–54);
for the Lister strain, there would be 2.5 deaths per million
vaccinations (95% CI, 0–13); and for the NYCBH strain, there
would be 1.2 deaths per million vaccinations (95% CI, 0–5)
(Figure 2B and Table S2). Combining these estimates with the
number of expected cases of PVE leads to estimates of case-
fatality rates of 10%–50%. This range indicates the order of
magnitude of the case-fatality rate but should not be
interpreted as comprising strain-speciﬁc estimates in view
of the uncertainties involved, such as differences in case
ascertainment and case deﬁnitions among the studies.
Examination of the age dependence of all vaccination-
Figure 2. Estimated Frequency of Adverse Events after Vaccination with
Different Vaccinia Strains
(A) The estimated number of cases of PVE per million primary
vaccinations with different vaccinia strains, and (B) the estimated
number of deaths (all vaccination-related deaths and PVE-related deaths)
per million primary vaccinations with different vaccinia strains. Data in
the category ‘‘other’’ are included because they were used in the
statistical analysis and therefore, in the Bayesian setting, had an influence
on all estimates. The large error bars (95% CIs) indicate the uncertainty of
the estimates.
DOI: 10.1371/journal.pmed.0030272.g002
Figure 3. Age-Dependent Estimates for the Frequency of Adverse Events
after Vaccination
(A) The number of cases of PVE per million vaccinations expected in
different age groups for different vaccinia strains, and (B) the number of
deaths per million vaccinations expected in different age groups for
different vaccinia strains. The large error bars (95% CIs) indicate the
uncertainty of the estimates.
DOI: 10.1371/journal.pmed.0030272.g003
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Adverse Events and Vaccinia Strainsrelated mortality reveals a clear pattern for the Bern, Lister,
and NYCBH strains. For all three strains, mortality is
expected to be highest in children younger than 1 y old and
lowest in children approximately 2 y of age. Older children
and adults are expected to have a slightly increased mortality
rate (Figure 3B). For the other strains, there were not
sufﬁcient age-dependent data available to conduct the
analysis. After vaccinating children before the age of 1 y,
one expects 2.2 deaths per million vaccinations (95% CI, 0–
10) when vaccinating with the NYCBH strain, 13.0 deaths per
million vaccinations (95% CI, 0–49) when vaccinating with
the Lister strain, and 73.3 deaths per million vaccinations
(95% CI, 2–288) when vaccinating with the Bern strain. For
children aged 1–5 y, one expects 1.1 deaths per million
vaccinations (95% CI, 0–5) when vaccinating with the NYCBH
strain, 7.3 deaths per million vaccinations (95% CI, 0–28)
when vaccinating with the Lister strain, and 50.1 deaths per
million vaccinations (95% CI, 1–196) when vaccinating with
the Bern strain. The age dependence of mortality was
reﬂected in vaccination schemes for children in Germany
and Austria in the 1960s and 1970s, when children were not
allowed to receive a primary vaccination after the age of 3 y.
The higher levels of mortality in children younger than 1 y of
age are taken into account in the present pre-event
vaccination guidelines in the US, where age of ,1 y is a
contraindication for vaccination.
Mortality after Primary Vaccination and Revaccination
For the NYCBH, Lister, and Bern strains, there are also data
about the frequency of death after revaccination. In Figure 4,
the expected number of deaths per million vaccinations is
shown for different age groups for primary vaccination and
revaccination (see also Table S3). In general, one can say that
mortality after revaccination is much lower than that after
primary vaccination. The age dependence is roughly the same,
although for revaccination mortality seems to increase only
slightly with increasing age. The differences between strains
after revaccination are similar to those after primary
vaccination: the NYCBH strain caused the lowest rate of
adverse events, the Lister strain caused an intermediate rate,
and the Bern strain clearly caused the highest rate.
Expected Death Toll during a Present-Day Mass
Vaccination Campaign
These results can be used to estimate the number of deaths
during a mass vaccination campaign for a population with a
given population size, age distribution, and vaccination
history. We present results for the Netherlands (population,
16 million) and Germany (population, 82 million). Both
countries have stockpiled smallpox vaccines based on the
Lister strain. We used population age distributions based on
recent national demographic data for both countries. We
assumed that everybody older than 30 y had been vaccinated
before, and that 20% of the population had a contra-
indication for vaccination. These assumptions are rough
approximations because vaccination programs were reduced
gradually until they were stopped in the mid-1970s. Under
these assumptions, in the Netherlands, mass vaccination with
the NYCBH strain would lead to 9.8 deaths per million
vaccinations (95% CI, 0–30), mass vaccination with the Lister
strain would lead to 55.1 deaths per million vaccinations
(95% CI, 7–182), and mass vaccination with the Bern strain
would lead to 303.5 deaths per million vaccinations (95% CI,
19–1,093). In Germany, mass vaccination with the NYCBH
strain would lead to 46.2 deaths per million vaccinations
(95% CI, 6–142), mass vaccination with the Lister strain
would lead to 268.5 deaths per million vaccinations (95% CI,
39–875), and mass vaccination with the Bern strain would
lead to 1,381 deaths per million vaccinations (95% CI, 94–
4,909). These estimates could be reﬁned if precise knowledge
of the frequency and distribution of contraindications were
available and if more were known about the duration of
immunity after vaccination.
Discussion
Our analysis provides quantitative evidence for the strain-
based differences in the occurrence of adverse events
described by Fenner et al. [22]. Vaccination with the NYCBH
Figure 4. Estimates for the Frequencies of Adverse Events after Primary
and Re-Vaccination
The expected number of deaths per million primary vaccinations and
revaccinations with (A) the NYCBH strain, (B) the Lister strain, and (C) the
Bern strain for different age groups. The large error bars (95% CIs)
indicate the uncertainty of the estimates.
DOI: 10.1371/journal.pmed.0030272.g004
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Adverse Events and Vaccinia Strainsstrain is expected to cause a low rate of adverse events,
whereas vaccination with the Lister strain is expected to
cause an intermediate rate of adverse events, and vaccination
with the Bern strain is expected to cause a high rate of
adverse events. The frequency of occurrence of adverse
events is shown to be age dependent. Combined with
demographic data and information about past vaccination
schemes, our estimates can be used to provide information
about the number of deaths and cases of PVE that are to be
expected during a smallpox vaccination campaign. This could
be a mass vaccination campaign, or it could be a campaign
targeting speciﬁc age groups in the population (e.g., school-
children and military recruits). Underlying reasons for the
observed age dependence might be the maturation of the
immune system during childhood and the age-dependent
prevalence of certain diseases that impair the immune system
and were not recognized in vaccinees at the time of
vaccination. A similar age dependence was shown to exist
for mortality after smallpox infection [27]. However, the
analysis also shows that the support for the age dependency
of the data is not strong, and the uncertainties of the
estimates, as given in the 95% CIs, are large.
At present, there are efforts to develop second-generation
vaccines produced with cell cultures under modern labora-
tory standards, but these vaccines are not yet licensed [28,29].
As long as they have not been used in large-scale vaccination
programs, we cannot know whether they cause fewer adverse
events than ﬁrst-generation vaccines, because the frequency
of adverse events is too low to be reliably estimated in Phase
1, Phase 2, and Phase 3 vaccine trials. Therefore, our present
knowledge of adverse events after smallpox vaccination is
primarily based on what we know from pre-eradication
smallpox vaccination programs. Of course, there are many
caveats in applying estimates derived from historical data to
modern society, many of which have been discussed in the
literature [18]. The techniques of vaccine production and
quality control have improved [28], and education, training,
and screening protocols are implemented with great care [7],
such that fewer adverse events might occur. On the other
hand, diagnostic techniques and validity have improved, such
that it can be decided with improved accuracy whether an
observed condition is attributable to smallpox vaccination.
In present vaccination programs, more-rigid screening
might be implemented before vaccination to select against
persons with a contraindication. On the other hand, the
fraction of the population with immune deﬁciencies, aller-
gies, or other contraindications is thought to be much larger
than it was some decades ago, so that even with improved
screening the frequency of adverse events might increase.
Also, improved diagnostic methods and better surveillance
might lead to more-complete reporting and, therefore, an
increase in the reported frequency of adverse events. In the
recent US vaccination campaign involving military personnel,
the fraction of medical exemptions from vaccination was less
than 20%, which contrasts with our assumption above. At the
same time, the frequency of adverse events was less than
expected on the basis of historical data [5]. However, the
target population of the program was a very speciﬁc
population group with a better health status, on average,
than the general population.
As the recent vaccination campaign in the US has shown,
adverse events may occur that were observed only incidentally
in pre-eradication times. During the vaccination campaign
conducted in 2003–2004 among civilian volunteers and
military personnel, an unexpectedly high frequency of
myopericarditis occurred [30,31]. Although the rate of cardiac
ischemic events was not higher than expected in the
vaccinated population, and the frequency of anticipated
adverse events was even lower than expected on the basis of
historical records, the unanticipated high frequency of
myopericarditis led to negative publicity for the vaccination
program and to a plateau in the numbers of vaccinations. It is
difﬁcult to assess retrospectively whether some fraction of
cardiac deaths in the pre-eradication era could have been
attributed to smallpox vaccination but were not recorded as
such. In an analysis of death certiﬁcates from the period after
the mass vaccination campaign in New York City in 1947,
Thorpe et al. [32] concluded that an increase in the number of
cardiac deaths after vaccination could not be shown. However,
their statistical analysis was not undisputed, and the results
depended on the underlying assumptions [33]. The recent US
vaccination experience emphasizes the importance of accu-
rate surveillance of adverse events after vaccination, com-
bined with accurate statistical analysis of those data. Statistical
analysis can provide a basis for deﬁning threshold values and,
therefore, tools for deciding about continuation or changes in
vaccination programs. In particular, it might help in weighing
the advantages and disadvantages of ring vaccination against
those of mass vaccination. Such a decision, however, will
include more than numerical estimates; that is, it will also have
to take into account what is politically and socially acceptable
at the moment of implementing the vaccination program.
More-detailed information about the proportion of persons
vaccinated in every age group, the duration of immunity after
vaccination, and the proportion of persons in each age group
with a contraindication is necessary for a more precise
calculation of the frequencies of adverse events expected in
speciﬁc populations.
A limitation of our analysis lies in the variable quality of
the historical data, which cannot be checked for reliability
retrospectively. The data reported in different studies could
be based on different methods of case ascertainment and
different case deﬁnitions. The implementation of vaccination
programs, pre-vaccination screening, and the vaccination
methods might have been different in different countries.
Also, there are large differences in the surveillance and
reporting of adverse events. We found a clear time trend in
the occurrence of adverse events that reﬂected improvements
in quality control and standardization of vaccine production
as advocated by the WHO [22,26]. But intensiﬁed screening
for contraindication toward the end of the eradication
program might also have contributed to decreased inciden-
ces. The Bayesian methods used here offer an opportunity to
take some of the heterogeneities into account by including
the effect of study methodology in the statistical analysis.
Therefore, Bayesian methods allow a modern statistical
analysis of these extensive historical datasets.
Our analysis shows that the frequency of serious adverse
effects of smallpox vaccination is considerably higher for the
Lister strain than for the NYCBH strain. Previous analyses
discussing vaccination as a response to a bioterrorist attack
with smallpox [34,35] have been based almost exclusively on
estimates for the NYCBH strain obtained from the national
surveillance study of Lane et al. [14]. Furthermore, in
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Adverse Events and Vaccinia Strainsmodeling studies, such as those published by Kaplan et al.
[10], Halloran et al. [9], and Porco et al. [13], the number of
deaths after vaccination was estimated as one per million
vaccinations and was independent of the ages of the
individuals vaccinated. Our analysis places these estimates
on the lower end of a range of estimates for the NYCBH
strain and shows that estimates for the Lister strain are even
considerably higher. This implies that estimates based on the
NYCBH strain cannot easily be used to estimate the effects of
vaccination in European countries, where most of the
existing stockpiles of smallpox vaccine are based on the
Lister strain. On the basis of our age-speciﬁc estimates,
country-speciﬁc estimates can be derived for the expected
number of deaths after vaccination for each vaccinia strain,
the age distribution of the target population, and the
population’s prevaccination history. Policy makers planning
for an emergency response in case of a smallpox outbreak in
Europe should be aware of the increased risk of adverse
events associated with vaccination with the Lister strain,
compared with the NYCBH strain.
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Editors’ Summary
Background. For thousands of years, smallpox was one of the world’s
most-feared diseases. This contagious disease, caused by the variola
virus, historically killed about 30 percent of the people it infected. Over
the centuries, it probably killed more people than all other infectious
diseases combined, but it was also the first disease to be prevented by
vaccination. In 1796, the English physician Edward Jenner rubbed pus
from the spots of a milkmaid with cowpox into scratches on a young
boy’s arm; according to folklore, people who caught cowpox, a related
but mild disease of cows, were protected against smallpox. Six weeks
later, after a mild bout of cowpox, when the boy was challenged with
pus from a smallpox patient, he did not develop smallpox. This
vaccination procedure was later refined so that people were inoculated
with pure preparations of live vaccinia virus, which is closely related to
the smallpox and cowpox viruses, and by 1979 a global vaccination
campaign had totally eradicated the disease.
Why Was This Study Done? Smallpox vaccination has some adverse
effects. In particular, vaccinia virus occasionally infects the brain. This so-
called post-vaccination encephalitis can cause permanent brain damage
and, it has been estimated, kills one vaccinee in every million.
Consequently, as smallpox became rarer, the dangers of vaccination
began to outweigh its benefits. Routine smallpox vaccination stopped in
the US in 1972, and in 1980 the World Health Organization
recommended that all countries stop vaccination. Now, however, there
are fears that smallpox may be used for bioterrorism. If this did happen,
exposed individuals and their contacts, possibly even whole populations,
would have to be vaccinated as quickly as possible (very few people now
have strong immunity to smallpox). Many countries have stockpiles of
smallpox vaccines for this eventuality, but these contain different
vaccinia virus strains. In this study, the researchers examined historical
data to discover whether these strains differ in their potential to cause
encephalitis and death. This information should help public-health
officials plan their vaccination strategies in response to a bioterrorism
attack with smallpox.
What Did the Researchers Do and Find? The researchers collected data
from published studies on smallpox vaccination and adverse events from
several countries from the late 1950s onwards. They then used these
data to extrapolate how often the different vaccinia strains might cause
encephalitis and death if they were used today in vaccination programs.
They estimate that vaccinating with the New York City Board of Health
(NYCBH) strain, which is stockpiled in the US, might cause 2.9 cases of
post-vaccination encephalitis and 1.4 deaths per million vaccinated
individuals. In contrast, the Lister strain, which is stockpiled in many
European countries, might cause 26.2 cases of post-vaccination
encephalitis and 2.5 deaths per million vaccinees. For both strains,
vaccination of children younger than 1 year old would cause the highest
death rate, and individuals being re-vaccinated would be less likely to die
than those being vaccinated for the first time. Finally, the researchers use
their figures to estimate that about ten people would die if mass
vaccination with the NYCBH strain were used in the Netherlands
(population 16 million), whereas 55 people would die if the Lister strain
were used.
What Do These Findings Mean? The data used in this study are of
variable quality, so the figures calculated by the researchers are only
estimates. For instance, given the scatter of the original data, mass
vaccination in the Netherlands with the Lister strain might cause
anywhere between seven and nearly 200 deaths. However, the study
clearly suggests that more serious adverse events would occur after
vaccination with the Lister strain than after vaccination with the NYCBH
strain. It also indicates that even in the US, where the NYCBH vaccine
strain is stockpiled, previous analyses of the effects of vaccination in
response to a bioterrorist attack have probably underestimated how
many people might die from post-vaccination encephalitis. Public-health
decision makers should incorporate these new estimates into their
planning for a smallpox outbreak. These increased estimates of adverse
events after vaccination might, for example, make mass vaccination with
the Lister strain of vaccinia virus less acceptable. Instead, public-health
officials might decide to rely on vaccination of only the people directly
exposed to released smallpox virus and their close contacts (ring
vaccination) to contain a smallpox outbreak.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030272.
  World Health Organization, information on smallpox and preparedness
in the event of a smallpox outbreak
  MedlinePlus encyclopedia entry on smallpox
  US National Institute of Allergy and Infectious Diseases, patient fact
sheet on smallpox
  US Centers for Disease Control and Prevention, information for
patients and professionals on smallpox
  Wikipedia page on smallpox (note that Wikipedia is a free online
encyclopedia that anyone can edit)
  Wellcome Library MedHist, links to information on the history of
smallpox vaccination
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